AstraZeneca Pharma India Limited — Important, 30-05-2025: General Updates

AstraZeneca Pharma India has announced a board meeting to review the financial results for the quarter and half-year. The company secured approval to import and market Benralizumab (Fasenra) 30 mg/ml injection for an additional use as an add-on treatment for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This expanded indication could boost its presence and revenue potential in the specialty biologics market.